Genetic terms, population genetics and imprinting

Penetrance and expressivity are often confused. Penetrance is a binary concept—either the genotype produces a phenotype or it does not—whereas expressivity captures the spectrum of severity among those who are affected. A disease may be fully penetrant but highly variable in expressivity, as seen in Marfan syndrome, where some individuals develop life‑threatening aortic aneurysms while others have only mild skeletal features.

Pleiotropy explains why a single genetic test can have implications for multiple organ systems. For instance, a pathogenic BRCA1 variant raises risk for breast, ovarian, pancreatic, and prostate cancers, reflecting the gene’s role in DNA repair across diverse tissues.

Anticipation is most famously linked to trinucleotide repeat disorders. The repeat length expands during meiosis, crossing a pathogenic threshold in the next generation and thereby producing earlier onset. This phenomenon underscores the importance of measuring repeat size in families with Huntington disease, myotonic dystrophy, or fragile X syndrome.

Epistasis can mask or modify the phenotype of a primary mutation. In cystic fibrosis, certain modifier genes influence lung disease severity, illustrating that genotype‑phenotype correlations are rarely linear.

Mosaicism and heteroplasmy illustrate that not all cells carry the same genetic information. In mitochondrial diseases, the proportion of mutant mtDNA (heteroplasmy level) determines whether a patient remains asymptomatic or develops multisystem disease. Similarly, somatic mosaicism for a pathogenic variant can result in a localized skin disorder without systemic involvement.

Uniparental disomy can have two major consequences: (1) unmasking a recessive mutation when the other parental allele is absent, and (2) disrupting normal imprinting patterns. Recognising UPD is crucial when a child presents with a recessive disorder despite only one carrier parent being identified.

Linkage analysis and Hardy‑Weinberg equilibrium (HWE) are foundational tools for population genetics and for mapping disease genes.

Linkage refers to the tendency of loci that are physically close on a chromosome to be inherited together. The recombination fraction (θ) quantifies this tendency, ranging from 0 (complete linkage) to 0.5 (independent assortment). In human genetics, linkage maps are built from pedigrees using markers such as short tandem repeats (STRs) or single‑nucleotide polymorphisms (SNPs). Modern high‑density SNP arrays enable construction of linkage groups with fine resolution, analogous to the wheat linkage maps described in recent agronomic studies, where markers were organised into groups using LOD thresholds of 2–10 and average intervals of 1.66 cM/marker. Although the wheat data are plant‑specific, the principle that tighter marker spacing improves map accuracy applies equally to human linkage studies. ^[1]

HWE predicts genotype frequencies from allele frequencies in a large, randomly mating population with no selection, mutation, migration, or drift. The equation is:

p² + 2pq + q² = 1

where p = frequency of the dominant allele, q = frequency of the recessive allele, p² = homozygous dominant, 2pq = heterozygous, q² = homozygous recessive.

Example calculation (illustrative):
Suppose cystic fibrosis (CF) has a carrier frequency of 1 in 25 in a population. The carrier frequency equals 2pq = 1/25 = 0.04. Assuming p ≈ 1 (the disease allele is rare), q ≈ 0.02. The expected disease prevalence (q²) is 0.0004, or 1 in 2,500, matching observed CF incidence.

Deviations from HWE may signal genotyping errors, population stratification, or genuine biological forces such as selection. In clinical genetics, checking HWE for control cohorts ensures that association studies are not confounded.

When a disease locus is tightly linked to a marker (θ ≈ 0), the marker allele frequencies in affected families differ from those in the general population. This principle underlies genome‑wide association studies (GWAS), where millions of SNPs are tested for association with disease phenotypes. Significant associations often reflect linkage disequilibrium (LD) with the causal variant, a concept that parallels the high collinearity observed between genetic and physical positions of markers in wheat linkage maps. ^[1]

Imprinting disorders arise when the normal pattern of mono‑allelic expression is disturbed. The two classic neurodevelopmental syndromes that illustrate this principle are Prader‑Willi syndrome (PWS) and Angelman syndrome (AS). Both map to the same chromosomal region, 15q11‑q13, but the clinical picture differs dramatically depending on whether the paternal or maternal allele is affected.

• In PWS the genes that are normally active only on the paternal chromosome (e.g., SNRPN, NDN) are absent or silenced, leaving only the silent maternal copies.
• In AS the UBE3A gene, which is expressed only from the maternal allele in the brain, is lost, while the paternal copy remains epigenetically silenced.

Prader‑Willi syndrome

• Neonatal hypotonia, poor feeding → later hyperphagia and obesity
• Short stature, small hands/feet, hypogonadism
• Intellectual disability, behavioural problems

Angelman syndrome

• Severe speech impairment, frequent laughter, “happy puppet” demeanor
• Ataxia, seizures, microcephaly
• Profound intellectual disability

The contrasting phenotypes underscore how the same genomic region can give rise to opposite clinical pictures when the imprinting error involves different parental alleles.

Methylation‑specific PCR or multiplex ligation‑dependent probe amplification (MLPA) is the first‑line test because it detects >99 % of cases by revealing the parental‑specific methylation pattern. If methylation is abnormal, further studies (deletion mapping, UPD analysis, sequencing) clarify the underlying mechanism.

• Both disorders are lifelong; management is multidisciplinary.
• Early nutritional support in PWS prevents failure to thrive, while later appetite control mitigates obesity.
• In AS, seizure control, speech therapy, and behavioural interventions are central.
• Growth hormone therapy improves stature and body composition in PWS; it is also used in AS for height and bone health.

1. Misinterpretation of methylation results – The assay distinguishes only the presence or absence of the paternal or maternal methylation imprint; it does not differentiate between a deletion and UPD. Without follow‑up testing, the precise genetic cause remains unknown, which is essential for recurrence risk counselling.

2. Overlooking mosaicism – Low‑level mosaic deletions or UPD may produce borderline methylation signals, leading to false‑negative results. Repeat testing on a different tissue (e.g., buccal cells) can improve detection.

3. Confusing phenotypic overlap – Some features (e.g., hypotonia, developmental delay) are shared with other neurogenetic conditions. A thorough clinical assessment is required before ordering imprinting studies.

4. Neglecting parental testing – Determining whether a deletion is de novo or inherited influences recurrence risk. Failure to test parents can result in inaccurate genetic counselling.

5. Assuming all cases are imprinting‑related – Approximately 5 % of Angelman cases are due to UBE3A point mutations without imprinting defects; these require sequencing.

Imprinting disorders are encountered across several clinical specialties:

• Paediatrics & genetics – First‑line assessment of infants with hypotonia, feeding difficulties, or atypical neurobehaviour.
• Endocrinology – Management of growth hormone deficiency and hypogonadism in PWS; monitoring of bone health in AS.
• Neurology – Seizure control in Angelman syndrome; evaluation of sleep disturbances common to both conditions.
• Obstetrics & prenatal diagnostics – Non‑invasive prenatal testing (NIPT) can detect 15q11‑q13 deletions; invasive testing (CVS/amniocentesis) with methylation analysis is offered when ultrasound suggests a syndrome.
• Psychiatry – Behavioural phenotypes (e.g., compulsivity in PWS, frequent laughter in AS) guide targeted behavioural therapies.

In each setting, the diagnostic algorithm begins with a clinical suspicion, proceeds to methylation testing, and then branches according to the result, as illustrated in the flowchart above.